Last reviewed · How we verify
rBet v1-FV — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
rBet v1-FV (rBet v1-FV) — Allergopharma GmbH & Co. KG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| rBet v1-FV TARGET | rBet v1-FV | Allergopharma GmbH & Co. KG | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- rBet v1-FV CI watch — RSS
- rBet v1-FV CI watch — Atom
- rBet v1-FV CI watch — JSON
- rBet v1-FV alone — RSS
Cite this brief
Drug Landscape (2026). rBet v1-FV — Competitive Intelligence Brief. https://druglandscape.com/ci/rbet-v1-fv. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab